Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Baker Hughes Sells Waygate Technologies to Hexagon for $1.45 Billion 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
Meta Is Building an AI Version of Mark Zuckerberg to Interact With Employees 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
AI Deradicalization Tools: How Chatbots Could Help Combat Violent Extremism Online 
Jefferies Upgrades Starbucks to Hold as China JV Deal Closes and U.S. Business Shows Signs of Recovery 
Chinese Cars in Europe: Consumer Trust Is Shifting Fast 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
AUSTIN, Texas, April 12, 2016 -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer, today announced the closing of its initial public offering of 5,481,940 shares of its common stock at an initial public offering price of $10.00 per share, which includes the partial exercise by the underwriters of their option to purchase an additional 481,940 shares of common stock. The shares began trading on The NASDAQ Global Market on April 7, 2016 under the symbol “AGLE.” The net proceeds to Aeglea BioTherapeutics, Inc. from the sale of the shares in the offering are estimated to be approximately $47.1 million, after deducting underwriting discounts and commissions and estimated offering expenses.
UBS Investment Bank, BMO Capital Markets and Wells Fargo Securities are acting as joint book-running managers for the offering. Needham & Company is acting as co-manager.
A registration statement relating to these securities was filed with the Securities and Exchange Commission and declared effective on April 6, 2016. The offering is being made only by means of a prospectus, copies of which may be obtained from the offices of UBS Securities LLC, Attention: Prospectus Department, 1285 Avenue of the Americas, New York, NY 10019, or by telephone: (888) 827-7275; BMO Capital Markets Corp., 3 Times Square, New York, NY 10036, Attention: Equity Syndicate Department, or by telephone: (800) 414-3627, or by email: [email protected]; or Wells Fargo Securities, LLC, 375 Park Avenue, New York, NY 10152, Attention: Equity Syndicate Department, or by telephone: (800) 326-5897, or by email at [email protected].
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Media Contacts: Kelly France, Ph.D. BrewLife 415.946.1076 [email protected] Ina McGuiness BrewLife 805.427.1372 [email protected]
